Company / Working Capital
Jazz Pharmaceuticals Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$1.9B
FY2025
5-year range
$1.7B / $3.6B
FY2021-FY2025
Trend
-46.4%
vs FY2024
Sector context
#21 of 213
Health Care
What the data says
Among 213 Health Care companies, Jazz Pharmaceuticals is in the top 10% for working capital. Working Capital has fluctuated over the past 10 years, ranging from $491M in FY2016 to $3.6B in FY2024.
Based on SEC 10-K filings.
$1.9B in FY2025 with a 5-year CAGR of -2.5%. Top quartile in the Health Care sector.
Remained stable around $1.9B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +4.8%
- 5-Year CAGR
- -2.5%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $1.9B Sector average $934.6M
▼
+105.8% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.5%, indicating a declining trend.
- In FY2025, working capital decreased 46.4% year-over-year.
- Ranks #21 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9B | -46.4% |
| FY2024 | $3.6B | +89.1% |
| FY2023 | $1.9B | +13.5% |
| FY2022 | $1.7B | -7.2% |
| FY2021 | $1.8B | -17.6% |
| FY2020 | $2.2B | +72.7% |
| FY2019 | $1.3B | +42.5% |
| FY2018 | $888.5M | +31.8% |
| FY2017 | $674.3M | +37.4% |
| FY2016 | $490.7M | -52.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026